logo
  

Takeda's Takhzyro Shows Positive Results In Prevention Of HAE Attacks In Phase 3 Study In Children

Takeda's takhzyro or lanadelumab demonstrated positive results in the prevention of hereditary angioedema attacks in phase 3 SPRING study in children ages 2 to less than 12 years.

In this study, hereditary angioedema patients received a dose of 150 milligrams (mg) every 4 weeks in patients 2 to less than 6 years and every 2 weeks in patients aged 6 to less than 12 years.

According to the study results, Takhzyro reduced the rate of Hereditary Angioedema or HAE attacks in children by a mean of 94.8% over the 52-Week treatment period compared to baseline. The majority of patients (76.2%) were attack-free during the 52-week treatment period with an average of 99.5% attack-free days.

No deaths or serious treatment-emergent adverse events (TEAEs) were reported during the study, and no patients withdrew from the study due to TEAEs. The most commonly reported TEAE was injection site pain, and most TEAEs were mild or moderate in severity.

The results are consistent with the favorable efficacy and safety profile of takhzyro observed in earlier studies with adult and adolescent patients.

The global regulatory filings is expected to begin in fiscal year 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Drug major Pfizer Inc. reported Tuesday higher earnings in its fourth quarter, above market estimates, and an all-time high revenues in its fiscal 2022. Meanwhile, the company projects sharply lower adjusted earnings and revenues in its fiscal 2023, below Wall Street estimates, reflecting projected decline for COVID-19 products. In pre-market activity on the NYSE, Pfizer shares were losing around Oil major Exxon Mobil Corp. (XOM) reported Tuesday that fourth-quarter net income was $12.75 billion or $3.09 per share, up from $8.87 million or $2.08 per share in the prior-year quarter. Excluding special items, adjusted earnings were $3.40 per share, compared to $2.05 per share in the prior-year... La Mirada, California-based Daiso California LLC is recalling certain Matsunaga Mini Shiruko Sand Biscuits citing undeclared soy, an allergen, the U.S. Food and Drug Administration said. The recall incolves Matsunaga Mini Shiruko Sand Biscuits with sku 4902773016966, packaged in four pink and cream bags chained together. Each individual serving is 25g for an entire product weight of 100g.
Follow RTT